União Europeia - sueco - EMA (European Medicines Agency)

bayer ag  - vardenafil - erektil dysfunktion - urologiska - behandling av erektil dysfunktion hos vuxna män. erektil dysfunktion är oförmågan att uppnå eller behålla en penile erektion som är tillräcklig för tillfredsställande sexuell prestanda. för att vivanza att vara effektiv, att en sexuell stimulering krävs. vivanza är inte avsett för användning av kvinnor.

União Europeia - sueco - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - upadacitinib - artrit, reumatoid - immunsuppressiva - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.  crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

União Europeia - sueco - EMA (European Medicines Agency)

novartis europharm ltd - valsartan, amlodipine (as amlodipine besilate) - hypertension - agenter som verkar på renin-angiotensinsystemet - behandling av essentiell hypertoni. imprida är indicerat för patienter vars blodtryck inte är adekvat kontrollerat om amlodipin eller valsartan monoterapi.

Suécia - sueco - Läkemedelsverket (Medical Products Agency)

mylan hospital as - cytarabin - injektions-/infusionsvätska, lösning - 100 mg/ml - cytarabin 100 mg aktiv substans - cytarabin

Suécia - sueco - Läkemedelsverket (Medical Products Agency)

mylan hospital as - cytarabin - injektions-/infusionsvätska, lösning - 20 mg/ml - cytarabin 20 mg aktiv substans - cytarabin

Suécia - sueco - Läkemedelsverket (Medical Products Agency)

karo pharma as - doxylaminvätesuccinat - filmdragerad tablett - 12,5 mg - doxylaminvätesuccinat 12,5 mg aktiv substans; propylenglykol hjälpämne; nykockin aluminiumlack hjälpämne - doxylamin

Suécia - sueco - Läkemedelsverket (Medical Products Agency)

karo pharma as - doxylaminvätesuccinat - filmdragerad tablett - 25 mg - propylenglykol hjälpämne; doxylaminvätesuccinat 25 mg aktiv substans - doxylamin

Suécia - sueco - Läkemedelsverket (Medical Products Agency)

karo pharma as - 2,4-diklorobensylalkohol; amylmetakresol; lidokainhydrokloridmonohydrat - sugtablett - 2,4-diklorobensylalkohol 1,2 mg aktiv substans; amylmetakresol 0,6 mg aktiv substans; lidokainhydrokloridmonohydrat 2,13 mg aktiv substans; sackaros hjälpämne; glukos, flytande hjälpämne - Övrigt

Suécia - sueco - Läkemedelsverket (Medical Products Agency)

karo pharma as - 2,4-diklorobensylalkohol; amylmetakresol; lidokainhydrokloridmonohydrat - sugtablett - sackaros hjälpämne; glukos, flytande hjälpämne; lidokainhydrokloridmonohydrat 2,13 mg aktiv substans; 2,4-diklorobensylalkohol 1,2 mg aktiv substans; amylmetakresol 0,6 mg aktiv substans; para-orange hjälpämne; nykockin hjälpämne - Övrigt

Suécia - sueco - Läkemedelsverket (Medical Products Agency)

karo pharma as - 2,4-diklorobensylalkohol; amylmetakresol; lidokainhydrokloridmonohydrat - sugtablett - amylmetakresol 0,6 mg aktiv substans; 2,4-diklorobensylalkohol 1,2 mg aktiv substans; lidokainhydrokloridmonohydrat 2,13 mg aktiv substans; sackaros hjälpämne; glukos, flytande hjälpämne; para-orange hjälpämne - Övrigt